伊立替康联合替吉奥二线治疗晚期胃癌临床观察  

Clinical Observation of Irinotecan Combined with S-1 in the Second Line Treatment of Advanced Gastric Carcinoma

作　　者：崔艳艳[1] 綦会霞[1] 

机构地区：[1]赤峰学院附属医院肿瘤内科,内蒙古赤峰024000

出　　处：《肿瘤基础与临床》2016年第6期498-500,共3页journal of basic and clinical oncology

摘　　要：目的观察伊立替康联合替吉奥二线治疗晚期胃癌的疗效及不良反应。方法 39例一线化疗失败的晚期胃癌患者,用伊立替康联合替吉奥方案进行二线治疗。结果 39例患者均可评价疗效,其中CR 0例,PR 14例,SD 15例,PD 10例,有效率为35.90%,疾病控制率为74.36%。主要不良反应为恶心、呕吐、腹泻、骨髓抑制等。结论伊立替康联合替吉奥二线治疗晚期胃癌近期疗效较好,不良反应可耐受,是晚期胃癌二线治疗可选择的化疗方案。Objective To observe the therapeutic effect and toxicities of irinotecan combined with S-1 in the second line treatment of advanced gastric carcinoma. Methods Thirty-nine patients progressive to fist line chemotherapy were enrolled,and received the second line treatment of irinotecan combined with S-1. Results Thirty-nine patients were evaluated efficacy, No patient reached CR, 14 patients PR, 15 patients SD, 10 patientsPS, the response rate was 35.90% ,the disease control rate was 74.36%. The major toxicities were nausea, vomiting, diarrhea, marrow suppression. Conclusion Irinotecan combined with S-1 is effective and safe in the second line treatment of ad- vanced gastric carcinoma.

关 键 词：伊立替康 替吉奥 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]